Tarsus Announces Pricing of Upsized $125.0 Million Public Offering

Group 1 - Tarsus Pharmaceuticals, Inc. announced the pricing of an upsized underwritten public offering of 2,808,988 shares at a public offering price of $44.50 per share, with expected gross proceeds of approximately$125.0 million before deductions [1] - The offering is expected to close on March 14, 2025, subject to customary closing conditions [1] - Underwriters have a 30-day option to purchase an additional 421,348 shares at the public offering price [1] Group 2 - Goldman Sachs & Co. LLC, BofA Securities, Barclays, and Oppenheimer & Co. are acting as joint book-running managers for the offering [2] - A registration statement for the shares was filed with the U.S. Securities and Exchange Commission (SEC) on February 29, 2024, and became effective upon filing [3] - A preliminary prospectus supplement related to the offering has been filed with the SEC and is available on their website [4] Group 3 - Tarsus Pharmaceuticals focuses on advancing its pipeline to address diseases with high unmet needs, particularly in eye care and infectious disease prevention [6] - The company’s FDA-approved product, XDEMVY, is for the treatment of Demodex blepharitis, and it is also developing TP-04 for Ocular Rosacea and TP-05 for Lyme disease prevention [6]